Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$62.0 million","upfrontCash":"Undisclosed","newsHeadline":"Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devastating Pulmonary Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"Undisclosed","newsHeadline":"Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"xCures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","amount":"$430.0 million","upfrontCash":"Undisclosed","newsHeadline":"Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endeavor BioMedicines Successfully Completes Phase 2a Trial of ENV-101 in Patients with Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"AyurMaya","pharmaFlowCategory":"D","amount":"$132.5 million","upfrontCash":"Undisclosed","newsHeadline":"Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENV-101 Phase 2a Shows Lung Function, Fibrosis Reversal in IPF","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Endeavor Biomedicines

    Menu

    Endeavor Biomedicines

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Endeavor Biomedicines

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ENV-101 Phase 2a Shows Lung Function, Fibrosis Reversal in IPF

              Details:

              ENV-101 (taladegib) is an oral small molecule inhibitor of the Hedgehog (Hh) signaling pathway. It is being evaluated in phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis.

              Lead Product(s): Taladegib

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ENV-101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 19, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endeavor Biomedicines

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines

              Details:

              Endeavor will use the financing proceeds to advance the clinical development of ENV-101, its lead candidate for the treatment of idiopathic pulmonary fibrosis.

              Lead Product(s): Taladegib

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ENV-101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: AyurMaya

              Deal Size: $132.5 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing April 24, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endeavor Biomedicines

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endeavor BioMedicines Successfully Completes Phase 2a Trial of ENV-101 in Patients with Idiopathic Pulmonary Fibrosis

              Details:

              ENV-101 (taladegib) is an oral small molecule inhibitor of the Hedgehog (Hh) signaling pathway. It is being evaluated in phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis.

              Lead Product(s): Taladegib

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ENV-101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 24, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endeavor Biomedicines

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)

              Details:

              Under the agreement, Endeavor has acquired exclusive worldwide rights to Hummingbird Bio’s HMBD-501, a next-generation HER3-targeted antibody-drug conjugate (ADC).

              Lead Product(s): HMBD-501

              Therapeutic Area: Oncology Product Name: HMBD-501

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: Hummingbird Bioscience

              Deal Size: $430.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endeavor Biomedicines

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

              Details:

              ENV-101 (taladegib) is a small-molecule inhibitor of the Hedgehog (Hh) signaling pathway, which plays a critical role in idiopathic pulmonary fibrosis disease pathology.

              Lead Product(s): Taladegib

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ENV-101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endeavor Biomedicines

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)

              Details:

              The partnership helps identify patients whose cancers harbor the PTCH1 mutation and may be eligible for Endeavor’s clinical trial for ENV-101 (taladegib). The xCures platform also enables patients to find more suitable treatment options if they are ineligible.

              Lead Product(s): Taladegib

              Therapeutic Area: Oncology Product Name: ENV-101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: xCures

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endeavor Biomedicines

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib)

              Details:

              ENV-101 (taladegib), an orally available small molecule inhibitor of the Hedgehog signaling pathway, has already demonstrated preliminary clinical efficacy and safety in nearly 200 subjects enrolled across six completed studies.

              Lead Product(s): Taladegib

              Therapeutic Area: Oncology Product Name: ENV-101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endeavor Biomedicines

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline

              Details:

              Proceeds will support the Endeavor’s pipeline, including ENV-101 (taladegib), a small molecule inhibitor of PTCH1 receptor, for the treatment of cancer and idiopathic pulmonary fibrosis and ENV-201, a small molecule inhibitor of ULK1/2 for the treatment of KRAS-driven cancers.

              Lead Product(s): Taladegib

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ENV-101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Ally Bridge Group

              Deal Size: $101.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing February 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endeavor Biomedicines

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devastating Pulmonary Disease

              Details:

              Proceeds from the financing will be used to advance taladegib, an inhibitor of the Hedgehog pathway, into two Phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis (IPF) in 2021.

              Lead Product(s): Taladegib

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ENV-101

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Omega Funds

              Deal Size: $62.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing January 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY